Uncategorized
Deep Dive Into Dynatrace Stock: Analyst Perspectives (13 Ratings)
Latest Ratings for DT Date Firm Action From To Feb 2022 Rosenblatt Maintains Buy Feb 2022 BTIG Downgrades Buy Neutral Feb 2022 Needham Maintains Buy View More Analyst Ratings for DT View the Latest Analyst Ratings read more
Analyst Expectations For Progyny’s Future
Latest Ratings for PGNY Date Firm Action From To Dec 2021 Jefferies Initiates Coverage On Buy Sep 2021 Berenberg Initiates Coverage On Buy Sep 2021 Barclays Maintains Overweight View More Analyst Ratings for PGNY View the Latest Analyst Ratings read more
Trump Family Tightens Grip On DeFi Platform World Liberty Financial
The Trump family has significantly increased its control over World Liberty Financial, a decentralized finance platform still under development. read more
Congressman Buys Up To $600K In Bitcoin ETF After Selling $1 Million In Goldman Sachs Stock: Committee Assignment Could Be Red Flag
A Congressman who bought shares of a Bitcoin (CRYPTO: BTC) ETF before President Donald Trump announced an Executi read more
Gold Rally Could Gain Momentum With Central Bank Buying And China Allocation, Analyst Says
Gold prices exceeded $3,000/oz, with potential to reach $3,500 if investment demand rises. China’s insurance sector and central banks may increase gold holdings, while ETF inflows signal growing retail interest. Trade policy uncertainty and a weaker U.S. dollar could further support prices. Latest Ratings for GOLD Date Firm Action From To Mar 2022 Jefferies Maintains…
Google’s New AI Travel Features Could Drive Major Growth In Search Volume: Analyst
On March 27, Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google introduced several new features across Search, Maps, and Gemini Latest Ratings for GOOGL Date Firm Action From To Feb 2022 MKM Partners Maintains Buy Feb 2022 Mizuho Maintains Buy Feb 2022 Piper Sandler Maintains Overweight View More Analyst Ratings for GOOGL View the Latest Analyst Ratings read…
FDA Approves AstraZeneca’s Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
FDA approved AstraZeneca’s Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma. read more